相关实验视频

Updated: May 20, 2025

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

外基因传递的HSPA9通过向多发性骨髓瘤中的TRIP13/USP1信号来促进博特佐米布耐药性

Min Shi¹, Na Shen¹, Xiangyu Liu¹

¹Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.

Cell communication and signaling : CCS

|March 27, 2025

概括

从耐药多发性髓瘤细胞中携带热冲击70 kDa蛋白9 (HSPA9) 的外体细胞传播了耐药性. 向HSPA9可以克服多发性骨髓瘤中的博特佐米布耐药性.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
细胞生物学细胞生物学

背景情况:

博尔特佐米布 (BTZ) 耐药性是多发性骨髓瘤 (MM) 的一个主要挑战.
外体细胞调解细胞间通信,并可以转移治疗抵抗.
热冲击70kDa蛋白9 (HSPA9) 与癌症进展有关.

研究的目的:

阐明多发性骨髓瘤中外体介导的博特佐米布耐药性的机制.
调查HSPA9在BTZ抗性MM细胞分泌的外体中的作用.
确定克服BTZ耐药性的潜在治疗点.

主要方法:

外体特征 (纳米粒子跟踪分析,TEM).
通过HSPA9查 (LC-MS,数据库).
在体外测试 (细胞计数,西部涂抹,殖民地形成).
分子相互作用研究 (co-IP,免疫光,蛋白质切断).
在体内模型 (光学成像,异种移植).

主要成果:

在血清外体和BTZ抗性MM患者中,HSPA9的调控升高.
外体HSPA9促进了MM增殖和BTZ耐药性.
在HSPA9中,USP1被调用来稳定HSPA9-USP1-TRIP13复合体,防止TRIP13的退化.
这种复杂的抑制逆转了BTZ电阻.

结论:

携带HSPA9的外基因组通过USP1/TRIP13通路传递博特佐米布耐药性.
外体HSPA9是一种潜在的治疗点,用于克服多发性骨髓瘤中博特佐米布耐药性.
这项研究揭示了一个新的分子机制,驱动MM的治疗耐药性.

关键词:

异构体是什么? 异构体是什么? 外构体是什么?在HSPA9中,HSPA9是HSPA9标准.多发性骨髓瘤是一种多发性骨髓瘤.在 TRIP13 中,USP1 USP1 的时间

更多相关视频

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

相关概念视频

Export of Misfolded Proteins out of the ER

Export of Misfolded Proteins out of the ER

After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...

Overview of Exosomes

Overview of Exosomes

Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...